Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Arvind Gadekar"'
Autor:
Ashok K. Das, Sanjay Kalra, Shashank Joshi, Ambrish Mithal, K. M. Prasanna Kumar, A. G. Unnikrishnan, Hemant Thacker, Bipin Sethi, Subhankar Chowdhury, Amarnath Sugumaran, Ashwini Satpathy, Arvind Gadekar, Shalini K. Menon, Renuka Neogi, Deepa Chodankar, Chirag Trivedi, S. K. Wangnoo, A. H. Zargar, Nadeem Rais, LANDMARC study group
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 6, Iss 5, Pp n/a-n/a (2023)
Abstract Introduction LANDMARC (CTRI/2017/05/008452), a prospective, observational real‐world study, evaluated the occurrence of diabetes complications, glycemic control and treatment patterns in people with type 2 diabetes mellitus (T2DM) from pan
Externí odkaz:
https://doaj.org/article/57997eb5dcc94d18a610e0249ced28fc
Autor:
Faruque Pathan, Su-Yen Goh, Achmad Rudijanto, Arvind Gadekar, Anand Jain, Nemencio Nicodemus Jr.
Publikováno v:
Journal of the ASEAN Federation of Endocrine Societies, Vol 33, Iss 1 (2018)
Objective: To provide real-world data on hypoglycaemia incidence in patients with type 1 (T1D) or type 2 diabetes (T2D) from the Southeast Asian cohort of the International Operations Hypoglycaemia Assessment Tool (IO HAT) study. Methodology: IO HAT
Externí odkaz:
https://doaj.org/article/363adbc7b0b743b5a5cf3ff499f56385
Autor:
Arvind Gadekar
Publikováno v:
International Journal of Advances in Medicine. 8:721
Eribulin is a unique microtubule inhibitor with mitotic and nonmitotic mechanisms of action. Eribulin has substantial activity in patients with pretreated (anthracycline and a taxane) advanced or metastatic breast cancer was confirmed by large-scale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fdd068efd476f783188badbf275ca4f
https://doi.org/10.18203/2349-3933.ijam20211451
https://doi.org/10.18203/2349-3933.ijam20211451